BiotechTube

LY2510924 + Carboplatin + Etoposide

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Extensive Stage Small Cell Lung Carcinoma

Conditions

Extensive Stage Small Cell Lung Carcinoma

Trial Timeline

Sep 1, 2011 → Aug 1, 2016

NCT ID
NCT01439568

About LY2510924 + Carboplatin + Etoposide

LY2510924 + Carboplatin + Etoposide is a phase 2 stage product being developed by Eli Lilly for Extensive Stage Small Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01439568. Target conditions include Extensive Stage Small Cell Lung Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01439568Phase 2Completed

Competing Products

20 competing products in Extensive Stage Small Cell Lung Carcinoma

See all competitors
ProductCompanyStageHype Score
ALPS12 + obinutuzumabChugai PharmaceuticalPhase 1
33
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue MedicationsDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecan + Atezolizumab + CarboplatinDaiichi SankyoPhase 1/2
41
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
SHR-1316 + Carboplatin + Etoposide + PlaceboJiangsu Hengrui MedicinePhase 3
77
Epirubicin plus SHR1210Jiangsu Hengrui MedicinePhase 2
52
Durvalumab plus chemotherapyAstraZenecaPhase 3
77
Durvalumab + Tremelimumab + Olaparib Pill + TremelimumabAstraZenecaPhase 1
33
Neoantigen DNA vaccine + DurvalumabAstraZenecaPhase 2
52
Etoposide with Carboplatin or Cisplatin + DurvalumabAstraZenecaPhase 2
52
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + CarboplatinAstraZenecaPhase 1
33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
52
Durvalumab + Cisplatin + Etoposide + CarboplatinAstraZenecaPhase 3
77
Durvalumab + Cisplatin + Carboplatin + EtoposideAstraZenecaPhase 3
77
Cisplatin + Carboplatin + Etoposide + Durvalumab + CeralasertibAstraZenecaPhase 2
52
Carboplatin + Cisplatin + Durvalumab + EtoposideAstraZenecaPhase 2
52
Carboplatin + Durvalumab + Etoposide + OlaparibAstraZenecaPhase 1/2
41
Durvalumab + Tremelimumab + Carboplatin + Cisplatin + EtoposideAstraZenecaPhase 3
77
Bomedemstat + AtezolizumabMerckPhase 1/2
41

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85